
Audio By Carbonatix
Breast cancer can resurface after remaining dormant for 15 years following successful treatment, a study has found.
Women with large tumours and cancer that had spread to the lymph nodes had the highest 40% risk of it coming back.
Researchers writing in the New England Journal of Medicine said extending treatment with hormone therapy could reduce the risk of it recurring.
Scientists analysed the progress of 63,000 women for 20 years.
All had the most common form of breast cancer.
This is a type fuelled by the hormone oestrogen which can stimulate cancer cells to grow and divide.
Every patient received treatments such as tamoxifen or aromatase inhibitors which block the effects of oestrogen or shut off the hormone's supply.
Although after five years of treatment their cancers had gone, over the next 15 years a steady number of women found that their cancer spread throughout their body - some up to 20 years after diagnosis.
Women who originally had large tumours and cancer that had spread to four or more lymph nodes were at highest risk of the cancer returning the next 15 years, the study said.
Women with small, low-grade cancers and no spread to the lymph nodes had a much lower 10% risk of cancer spread over that time.
'Remarkable'
Lead researcher Dr Hongchao Pan, from University of Oxford, said: "It is remarkable that breast cancer can remain dormant for so long and then spread many years later, with this risk remaining the same year after year and still strongly related to the size of the original cancer and whether it had spread to the (lymph) nodes."
Doctors have long known that five years of tamoxifen reduces the risk of recurrence by about a third in the five years after stopping treatment.
Recent research has suggested that extending hormone therapy to 10 years may be more effective at preventing breast cancer recurrence and death.

But there are side effects with hormone treatments which can affect patients' quality of life and cause them to stop taking the pills.
These include menopausal symptoms, osteporosis, joint pain and carpal tunnel syndrome.
Prof Arnie Purushotham, senior clinical adviser at Cancer Research UK, which funded the study, said that since the research began, new drugs had been used to treat breast cancer and those worked in different ways to tamoxifen.
He said: "It's vital that work continues to better predict which cancers might return.
"We also need to know what the difference for women might be in taking hormone therapies for 10 years instead of five, the side effects and how this affects patients' quality of life."
Latest Stories
-
Sampa chieftaincy dispute: Sammordua dragged to court for contempt
41 seconds -
Okyere Baafi calls for suspension of Publican AI system over ‘serious flaws’
3 minutes -
OSP uncovers “secret collusion” between fuel companies, NPA, GRA and National Security
9 minutes -
VIP Transport defends fare increase over rising fuel and maintenance costs
25 minutes -
LGBTQ+ issues not a priority for Ghanaians – Felix Kwakye Ofosu
39 minutes -
Kwakye Ofosu rejects NPP Minority’s call for apology over anti-LGBTQ bill
47 minutes -
Music giant Universal gets $64bn takeover offer
59 minutes -
NPP criticism of anti-LGBTQ Bill ‘nothing more than political posturing’ — Kwakye Ofosu
1 hour -
Joy FM was birthed over a bowl of fufu’ – Tommy Annan-Forson shares interesting story
1 hour -
World Athletics to introduce standalone World Marathon Championships from 2030
1 hour -
Africa’s voice in global journalism grows as funding, AI and misinformation shape newsrooms
1 hour -
First Atlantic Bank holds Annual General Meeting, reports strong growth and bold outlook for 2026
1 hour -
Ghanaian-founded fintech WeWire secures Canadian PSP license to bridge African, global payments
1 hour -
Uganda confirms 2027 AFCON dates
2 hours -
40 convicted in Northern Region crime crackdown
2 hours